Chief Accounting Officer Louise Kooij to Depart NewAmsterdam Pharma

summarizeSummary

NewAmsterdam Pharma announced that Chief Accounting Officer Louise Kooij will depart the company effective August 31, 2026, with a separation agreement in place.

check_boxKey Events

• Chief Accounting Officer Departure

  Louise Kooij will step down as Chief Accounting Officer effective August 31, 2026, by mutual agreement.

• Separation Agreement Terms

  Ms. Kooij will receive a lump sum equal to 12 months of her base salary, a pro-rated 2026 annual cash bonus, and accrued holiday/vacation days.

• Equity Vesting Extended

  Vesting of outstanding stock options and restricted stock units (RSUs) will be extended through January 10, 2027, with an exercise period until February 10, 2027.

• Restrictive Covenants

  The separation agreement includes confidentiality, non-compete, non-disparagement covenants, and a release of claims.

auto_awesomeAnalysis

The departure of a Chief Accounting Officer, even if amicable and planned, introduces a transition period for a key financial role. The company has outlined a standard separation package, including a lump sum, pro-rated bonus, and extended equity vesting, which aims to ensure an orderly transition and adherence to restrictive covenants. Investors will monitor the appointment of a successor and any potential impact on financial reporting.